Trial reportBMC pulmonary medicine2013
A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation.
Trial report in BMC pulmonary medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.The Cochrane database of systematic reviews · 2020Pooled it
- Pharmacokinetics and Bioequivalence Evaluation of Two Montelukast Sodium Chewable Tablets in Healthy Chinese Volunteers Under Fasted and Fed Conditions.Drug design, development and therapy · 2021Trial
- Effects of oral montelukast on pulmonary function and clinical symptoms in acute asthma exacerbations: a randomized, double-blind, placebo-controlled trial.Annals of medicine and surgery (2012) · 2024Article
- Pharmacokinetics and bioequivalence study of montelukast sodium oral soluble film and chewable tablet in healthy Chinese volunteers: randomized trials under fasting and fed conditions.Annals of translational medicine · 2023Article
- Article
- Effectiveness and Quality of Life with Montelukast in Asthma - A double-blind randomized control trial.Pakistan journal of medical sciences · 2019Article
- The acute management of asthma.Clinical reviews in allergy & immunology · 2015Review
- Critical asthma syndrome in the ICU.Clinical reviews in allergy & immunology · 2015Review
- Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function.Journal of immunology research · 2014Review
- Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?Drug design, development and therapy · 2014Review
- Effects of oral montelukast on airway function in acute asthma: A randomized trial.Lung India : official organ of Indian Chest SocietyArticle
- Comparison of oral montelukast with oral zileuton in acute asthma: A randomized, double-blind, placebo-controlled study.Lung India : official organ of Indian Chest SocietyArticle
- Comparison of oral montelukast with oral ozagrel in acute asthma: A randomized, double-blind, placebo-controlled study.Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukotriene receptor antagonists (LTRAs) are well established in the management of outpatient asthma. However, there is very little information as to their role in acute asthma exacerbations. We hypothesized that LTRAs may accelerate lung function recovery when given in an acute exacerbation.
methodsA randomized, double blind, placebo-controlled trial was conducted at the Aga Khan University Hospital to assess the efficacy of oral montelukast on patients of 16 years of age and above who were hospitalized with acute asthma exacerbation. The patients were given either montelukast or placebo along with standard therapy throughout the hospital stay for acute asthma. Improvements in lung function and duration of hospital stay were monitored.
results100 patients were randomized; their mean age was 52 years (SD +/- 18.50). The majority were females (79%) and non-smokers (89%). The mean hospital stay was 3.70 ± 1.93 days with 80% of patients discharged in 3 days. There was no significant difference in clinical symptoms, PEF over the course of hospital stay (p = 0.20 at day 2 and p = 0.47 at day 3) and discharge (p = 0.15), FEV1 at discharge (p = 0.29) or length of hospital stay (p = 0.90) between the two groups. No serious adverse effects were noted during the course of the study.
conclusionOur study suggests that there is no benefit of addition of oral montelukast over conventional treatment in the management of acute asthma attack.
trial registrationTRIAL REGISTRATION NUMBER: 375-Med/ERC-04.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.